Cargando…
End‐of‐life impact of concurrent diabetes mellitus and adrenal insufficiency as immune‐related adverse events in an advanced non‐small cell lung cancer patient
A 49‐year‐old man diagnosed with metastatic non‐small cell lung cancer was treated with immune checkpoint inhibitor (ICI) combination therapy (nivolumab + ipilimumab) as first‐line therapy. During the treatment course, the patient developed ICI‐associated diabetes mellitus and adrenal insufficiency,...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626334/ https://www.ncbi.nlm.nih.gov/pubmed/36195556 http://dx.doi.org/10.1111/1759-7714.14660 |